A private letter ruling made public last week signaled the IRS’s increasing willingness to approve spinoffs involving early-stage ventures. The ruling is especially significant to industries like pharmaceuticals and biotechnology, where products come to market through research, development, and regulatory-approval pipelines that can extend for many (unprofitable) years.
|
